12 results about "Calcitonin" patented technology

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.

This invention relates to the field of biomedical data processing technology, specifically to a stratification system for sepsis-related secondary invasive fungal infections based on laboratory data. The invention obtains the degree of static intestinal baseline damage by considering serum lactate concentrations at different historical testing times, temporal characteristics, and a preset maximum backtracking period; it obtains the cumulative dosage of antimicrobial drugs and the hourly cumulative distribution value of drug use based on the drug dosage distribution at different medication times within a neighborhood of the real-time trigger time; it obtains the overall degree of inflammation reduction and the hourly cumulative distribution value of inflammation regression based on the procalcitonin concentration distribution at testing times within a neighborhood; and it further obtains the net drug-induced intervention level. Based on the degree of static intestinal baseline damage and the net drug-induced intervention level, the fungal infection characteristics are stratified. This invention, by considering non-drug-induced interference, accurately obtains the comprehensive risk level of fungal infection, improving the effectiveness of fungal infection stratification.

This application discloses compounds of formula I for modulating the activity of calcitonin receptors and / or amylin receptors, as well as pharmaceutical compositions comprising the compounds disclosed herein. Methods for treating diseases or disorders related to calcitonin receptors and / or amylin receptors are also provided.

This invention belongs to the field of biotechnology, specifically relating to the application of calcitonin in promoting fish growth. By constructing a fish model lacking calcitonin synthesis function and combining this with experiments treating wild-type fish with exogenous calcitonin, the weight and body length of the fish model lacking calcitonin synthesis function were measured. The results showed that calcitonin significantly enhanced the weight and body length of zebrafish. Therefore, calcitonin can be applied to promote fish growth.

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

The application belongs to the technical field of microorganisms, and specifically discloses a fermented Lactobacillus muciapparius BLF03 and application thereof in resisting drug-resistant Staphylococcus aureus. The drug-resistant Staphylococcus aureus is Staphylococcus aureus resistant to drugs targeting beta-lactamase. The fermented Lactobacillus muciapparius BLF03 has been preserved in the China General Microbiological Culture Collection Center on November 6, 2025, and the preservation number is CGMCC No. 36521. The application provides the fermented Lactobacillus muciapparius BLF03 for resisting Staphylococcus aureus resistant to drugs targeting beta-lactamase, which can well relieve infection symptoms induced by drug-resistant Staphylococcus aureus, reduce the expression level of procalcitonin in the body after infection, and improve inflammatory stress response caused by infection, thereby providing a new safe and efficient strain selection for products resisting drug-resistant Staphylococcus aureus.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

This application belongs to the field of microbial technology, specifically disclosing the application of *Lactobacillus fermentum* BLF03 in anti-Candida activity. *Lactobacillus fermentum* BLF03 was deposited on November 6, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 36521. This application proposes a *Lactobacillus fermentum* BLF03 strain resistant to *Candida albicans* and *Candida krusei*, which can significantly inhibit the growth, reproduction, and hyphal transformation of *Candida albicans* and *Candida krusei* at the in vivo level, alleviate Candida-induced infection symptoms, reduce the expression level of the inflammatory marker procalcitonin (PCT) after Candida infection, improve the inflammatory stress response induced by infection, and has a significant protective effect against tissue damage caused by Candida invasion. It also has targeted preventive and adjunctive therapeutic effects on Candida infections in the urogenital tract and other sites, providing a new, safe, and highly effective strain for anti-Candida products.

The present application relates to the field of postoperative infection risk grading and early warning of hepatobiliary surgery, and in particular to a postoperative infection risk grading and early warning method based on clinical parameters. The content includes: collecting original clinical parameters and preprocessing to obtain preprocessed standardized clinical parameters; introducing a clinical basic weight, based on the preprocessed standardized clinical parameters, applying a multidimensional distribution mapping algorithm to calculate an infection risk score; dividing the risk level based on the infection risk score, and introducing a dynamic weighting mechanism with emphasis on effective updating to dynamically update the clinical basic weight. The method solves the problems of traditional postoperative infection risk assessment methods for hepatobiliary surgery, such as ignoring the complex high-order interaction and nonlinear correlation between body temperature, white blood cell count, procalcitonin, C-reactive protein and other indicators, being unable to adjust the parameter weight in real time according to the dynamic changes of the patient's postoperative condition, and lacking clear risk grading rules and limited engineering application value.

The present application relates to compounds of Formula I, which modulate calcitonin receptor and / or amylin receptor activity and are useful in the treatment of bone, metabolic, cardiovascular, neurodegenerative and other disorders. I